Protara Therapeutics Inc (TARA) - News Archive

Protara Therapeutics Expands Talent Pool Amid Promising Growth Trajectory: Implications for ShareholdersOn May 1, 2025, Protara Therapeutics, Inc. (Nasdaq: TARA), a forward-thinking clinical-stage biopharmaceutical comp...

Protara Therapeutics Reports Promising Trial Results Amidst Financial ChallengesProtara Therapeutics Inc. a biopharmaceutical company focused on advancing therapies for rare diseases, has recently highlighted significan...

Protara Therapeutics Unveils Promising Interim Results for TARA-002 in NMIBC at Prestigious Oncology Meeting Amidst the gathering of leading experts and trailblazers at the 25th Annual Meeting of the Society of Urologic...

Protara Therapeutics Presents Groundbreaking Insights from THRIVE-1 Study on Choline Deficiency and Liver Injury in Patients Dependent on Parenteral Support at ESPEN Conference NEW YORK, Sept. 09, 2024 - Protara Therape...

In a recent press release, Protara Therapeutics, Inc. has announced the grant of inducement non-qualified stock options to Lisa Schlesinger, the newly appointed Vice President, Head of New Product Development and Market...

Protara Therapeutics, a renowned innovative biopharmaceutical company, has recently announced the successful completion of an oversubscribed $45 million private placement financing round. The funding is expected to be i...

Protara Therapeutics, a pioneering clinical-stage biopharmaceutical company, has recently gained endorsement from the U.S. Food and Drug Administration (FDA) for its investigational intravenous (IV) Choline Chloride. Th...

Protara Therapeutics, a clinical-stage company focused on developing transformative therapies for cancer and rare diseases, has recently announced additional promising data from the Phase 1a dose-escalation component of...